Press Releases

 
Press Releases
  Date Title View
May 9, 2017
DURHAM, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the first quarter ended March 31, 2017. "We have made meaningful progress advancing both the short-course oral brin...
May 2, 2017
DURHAM, N.C., May 02, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to report financial ...
Apr 20, 2017
DURHAM, N.C., April 20, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host the Company's annual investor update event on April 27, 2017, from 4:30 p.m. to 6:30 p.m. ET....
Mar 2, 2017
- Successful Administration of IV Brincidofovir 50 mg in Ongoing Dose Escalation Study - - Demonstrates Favorable Safety and Tolerability Profile -- Conference Call at 8:30 a.m. ET Today -DURHAM, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical nee...
Feb 28, 2017
DURHAM, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and   commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix, will present a corporate overview at the ...
Feb 23, 2017
DURHAM, N.C., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2017 at 8:30 a.m. ET to report ...
Feb 22, 2017
-- Results show higher survival rate in adenovirus-infected patients with a virologic response to brincidofovir -- -- Mortality rates were lower in pediatric patients than in adult patients -- DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced the presentation of final data from the AdVise trial of brincid...
Jan 6, 2017
Study confirms drug levels for IV BCV 10 mg equivalent to oral BCV 100 mg   No gastrointestinal side effects seen with IV BCV at 10 and 25 mg doses DURHAM, N.C., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromi...
Jan 5, 2017
DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced the appointments of Randall Lanier, PhD, as Chief Science Officer and Roy W. Ware, PhD, MBA, as Chief Manufacturing and Tech...
Jan 4, 2017
DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 35th Annual J.P. Morgan Healthca...
Page:
1
... NextLast
= add release to Briefcase